Patents by Inventor Giovanni Parmigiani
Giovanni Parmigiani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240062916Abstract: Methods and systems for determining an expected disease treatment outcome upon treating a subject, methods and devices for selecting a treatment option for the subject, and methods of treating a subject for a disease, are described herein. The method can include receiving a plurality of subject characteristics for the subject; accessing a tree-based model corresponding to a treatment option for the disease, wherein the tree-based model is generated based on a plurality of prior patient characteristics and an associated treatment outcome for the corresponding treatment option; and determining from the plurality of subject characteristics and the tree-based model, an expected treatment outcome for the subject if the subject were treated with the corresponding treatment option.Type: ApplicationFiled: December 2, 2021Publication date: February 22, 2024Applicant: Foundation Medicine, Inc.Inventors: Leah COMMENT, Giovanni PARMIGIANI
-
Publication number: 20210317532Abstract: We found mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas as well as in gliblastomas that develop from these lower grade lesions. Those tumors without mutations in IDH1 often had mutations at the analogous R172 residue of the closely related IDH2 gene. These findings have important implications for the pathogenesis and diagnosis of malignant gliomas.Type: ApplicationFiled: November 6, 2020Publication date: October 14, 2021Inventors: Bert Vogelstein, Kenneth W. Kinzler, D. Williams Parsons, Xiaosong Zhang, Jimmy Cheng-Ho Lin, Rebecca J. Leary, Philipp Angenendt, Nickolas Papadopoulos, Victor Velculescu, Giovanni Parmigiani, Rachel Karchin, Sian Jones, Hai Yan, Darell Bigner, Chien-Tsun Kuan, Gregory J. Riggins
-
Patent number: 10894987Abstract: We found mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas as well as in glioblastomas that develop from these lower grade lesions. Those tumors without mutations in IDH1 often had mutations at the analogous R172 residue of the closely related IDH2 gene. These findings have important implications for the pathogenesis and diagnosis of malignant gliomas.Type: GrantFiled: November 16, 2016Date of Patent: January 19, 2021Assignees: The Johns Hopkins University, Duke UniversityInventors: Bert Vogelstein, Kenneth W. Kinzler, D. Williams Parsons, Xiaosong Zhang, Jimmy Cheng-Ho Lin, Rebecca J. Leary, Philipp Angenendt, Nickolas Papadopoulos, Victor Velculescu, Giovanni Parmigiani, Rachel Karchin, Sian Jones, Hai Yan, Darell D. Bigner, Chien-Tsun Kuan, Gregory J. Riggins
-
Patent number: 10837064Abstract: We found mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas as well as in gliblastomas that develop from these lower grade lesions. Those tumors without mutations in IDH1 often had mutations at the analogous R172 residue of the closely related IDH2 gene. These findings have important implications for the pathogenesis and diagnosis of malignant gliomas.Type: GrantFiled: March 22, 2018Date of Patent: November 17, 2020Assignees: The Johns Hopkins University, Duke UniversityInventors: Bert Vogelstein, Kenneth W. Kinzler, D. Williams Parsons, Xiaosong Zhang, Jimmy Cheng-Ho Lin, Rebecca J. Leary, Philipp Angenendt, Nickolas Papadopoulos, Victor Velculescu, Giovanni Parmigiani, Rachel Karchin, Sian Jones, Hai Yan, Darell Bigner, Chien-Tsun Kuan, Gregory J. Riggins
-
Patent number: 10704108Abstract: We found mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas as well as in gliblastomas that develop from these lower grade lesions. Those tumors without mutations in IDH1 often had mutations at the analogous R172 residue of the closely related IDH2 gene. These findings have important implications for the pathogenesis and diagnosis of malignant gliomas.Type: GrantFiled: September 17, 2018Date of Patent: July 7, 2020Assignees: The Johns Hopkins University, Duke UniversityInventors: Bert Vogelstein, Kenneth W. Kinzler, D. Williams Parsons, Xiaosong Zhang, Jimmy Cheng-Ho Lin, Rebecca J. Leary, Philipp Angenendt, Nickolas Papadopoulos, Victor Velculescu, Giovanni Parmigiani, Rachel Karchin, Sian Jones, Hai Yan, Darell Bigner, Chien-Tsun Kuan, Gregory J. Riggins
-
Publication number: 20190106752Abstract: We found mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas as well as in gliblastomas that develop from these lower grade lesions. Those tumors without mutations in IDH1 often had mutations at the analogous R172 residue of the closely related IDH2 gene. These findings have important implications for the pathogenesis and diagnosis of malignant gliomas.Type: ApplicationFiled: September 17, 2018Publication date: April 11, 2019Inventors: Bert Vogelstein, Kenneth W. Kinzler, D. Williams Parsons, Xiaosong Zhang, Jimmy Cheng-Ho Lin, Rebecca J. Leary, Philipp Angenendt, Nickolas Papadopoulos, Victor Velculescu, Giovanni Parmigiani, Rachel Karchin, Sian Jones, Hai Yan, Darell Bigner, Chien-Tsun Kuan, Gregory J. Riggins
-
Publication number: 20180282821Abstract: We found mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas as well as in gliblastomas that develop from these lower grade lesions. Those tumors without mutations in IDH1 often had mutations at the analogous R172 residue of the closely related IDH2 gene. These findings have important implications for the pathogenesis and diagnosis of malignant gliomas.Type: ApplicationFiled: March 22, 2018Publication date: October 4, 2018Inventors: Bert Vogelstein, Kenneth W. Kinzler, D. Williams Parsons, Xiaosong Zhang, Jimmy Cheng-Ho Lin, Rebecca J. Leary, Philipp Angenendt, Nickolas Papadopoulos, Victor Velculescu, Giovanni Parmigiani, Rachel Karchin, Sian Jones, Hai Yan, Darell Bigner, Chien-Tsun Kuan, Gregory J. Riggins
-
Publication number: 20170081730Abstract: We found mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas as well as in glioblastomas that develop from these lower grade lesions. Those tumors without mutations in IDH1 often had mutations at the analogous R172 residue of the closely related IDH2 gene. These findings have important implications for the pathogenesis and diagnosis of malignant gliomas.Type: ApplicationFiled: November 16, 2016Publication date: March 23, 2017Applicants: The Johns Hopkins University, Duke UniversityInventors: Bert Vogelstein, Kenneth W. Kinzler, D. Williams Parsons, Xiaosong Zhang, Jimmy Cheng-Ho Lin, Rebecca J. Leary, Philipp Angenendt, Nickolas Papadopoulos, Victor Velculescu, Giovanni Parmigiani, Rachel Karchin, Sian Jones, Hai Yan, Darell D. Bigner, Chien-Tsun Kuan, Gregory J. Riggins
-
Patent number: 9353418Abstract: We found mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas as well as in glioblastomas that develop from these lower grade lesions. Those tumors without mutations in IDH1 often had mutations at the analogous R172 residue of the closely related IDH2 gene. These findings have important implications for the pathogenesis and diagnosis of malignant gliomas.Type: GrantFiled: December 11, 2013Date of Patent: May 31, 2016Assignees: The Johns Hopkins University, Duke UniversityInventors: Bert Vogelstein, Kenneth W. Kinzler, D. Williams Parsons, Xiaosong Zhang, Jimmy Cheng-Ho Lin, Rebecca J. Leary, Philipp Angenendt, Nickolas Papadopoulos, Victor Velculescu, Giovanni Parmigiani, Rachel Karchin, Sian Jones, Hai Yan, Darell Bigner, Chien-Tsun Kuan, Gregory J. Riggins
-
Publication number: 20140377754Abstract: Human cancer is caused by the accumulation of mutations in oncogenes and tumor suppressor genes. To catalogue the genetic changes that occur during tumorigenesis, we isolated DNA from 11 breast and 11 colorectal tumors and determined the sequences of the genes in the Reference Sequence database in these samples. Based on analysis of exons representing 20,857 transcripts from 18,191 genes, we conclude that the genomic landscapes of breast and colorectal cancers are composed of a handful of commonly mutated gene “mountains” and a much larger number of gene “hills” that are mutated at low frequency. We describe statistical and bioinformatic tools that may help identify mutations with a role in tumorigenesis. These results have implications for understanding the nature and heterogeneity of human cancers and for using personal genomics for tumor diagnosis and therapy.Type: ApplicationFiled: August 5, 2014Publication date: December 25, 2014Inventors: Laura D. WOOD, D. Williams PARSONS, Sian JONES, Jimmy Cheng-Ho LIN, Tobias SJOBLOM, Thomas BARBER, Giovanni PARMIGIANI, Victor VELCULESCU, Kenneth W. KINZLER, Bert VOGELSTEIN
-
Publication number: 20140187764Abstract: We found mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas as well as in glioblastomas that develop from these lower grade lesions. Those tumors without mutations in IDH1 often had mutations at the analogous R172 residue of the closely related IDH2 gene. These findings have important implications for the pathogenesis and diagnosis of malignant gliomas.Type: ApplicationFiled: December 11, 2013Publication date: July 3, 2014Applicants: Duke University, The Johns Hopkins UniversityInventors: Bert VOGELSTEIN, Kenneth W. KINZLER, D. Williams PARSONS, Xiaosong ZHANG, Jimmy Cheng-Ho LIN, Rebecca J. LEARY, Philipp ANGENENDT, Nickolas PAPADOPOULOS, Victor VELCULESCU, Giovanni PARMIGIANI, Rachel KARCHIN, Sian JONES, Hai YAN, Darell BIGNER, Chien-Tsun KUAN, Gregory J. RIGGINS
-
Patent number: 8685660Abstract: We found mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas as well as in glioblastomas that develop from these lower grade lesions. Those tumors without mutations in IDH1 often had mutations at the analogous R172 residue of the closely related IDH2 gene. These findings have important implications for the pathogenesis and diagnosis of malignant gliomas.Type: GrantFiled: September 3, 2009Date of Patent: April 1, 2014Assignees: The Johns Hopkins University, Duke UniversityInventors: Bert Vogelstein, Kenneth W. Kinzler, D. Williams Parsons, Xiaosong Zhang, Jimmy Cheng-Ho Lin, Rebecca J. Leary, Philipp Angenendt, Nickolas Papadopoulos, Victor Velculescu, Giovanni Parmigiani, Rachel Karchin, Sian Jones, Hai Yan, Darell Bigner, Chien-Tsun Kuan, Gregory J. Riggins
-
Publication number: 20130196312Abstract: Human cancer is caused by the accumulation of mutations in oncogenes and tumor suppressor genes. To catalogue the genetic changes that occur during tumorigenesis, we isolated DNA from 11 breast and 11 colorectal tumors and determined the sequences of the genes in the Reference Sequence database in these samples. Based on analysis of exons representing 20,857 transcripts from 18,191 genes, we conclude that the genomic landscapes of breast and colorectal cancers are composed of a handful of commonly mutated gene “mountains” and a much larger number of gene “hills” that are mutated at low frequency. We describe statistical and bioinformatic tools that may help identify mutations with a role in tumorigenesis. These results have implications for understanding the nature and heterogeneity of human cancers and for using personal genomics for tumor diagnosis and therapy.Type: ApplicationFiled: September 28, 2011Publication date: August 1, 2013Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Laura D. WOOD, Williams D. PARSONS, Sian JONES, Jimmy LIN, Tobias SJÖBLOM, Thomas BARBER, Giovanni PARMIGIANI, Victor VELCULESCU, Kenneth W. KINZLER, Bert VOGELSTEIN
-
Publication number: 20120202207Abstract: We found mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas as well as in glioblastomas that develop from these lower grade lesions. Those tumors without mutations in IDH1 often had mutations at the analogous R172 residue of the closely related IDH2 gene. These findings have important implications for the pathogenesis and diagnosis of malignant gliomas.Type: ApplicationFiled: March 6, 2012Publication date: August 9, 2012Applicants: DUKE UNIVERSITY, THE JOHNS HOPKINS UNIVERSITYInventors: Bert VOGELSTEIN, Kenneth W. KINZLER, D. Williams PARSONS, Xiaosong ZHANG, Jimmy Cheng-Ho LIN, Rebecca J. LEARY, Philipp ANGENENDT, Nickolas PAPADOPOULOS, Victor VELCULESCU, Giovanni PARMIGIANI, Rachel KARCHIN, Sian JONES, Hai YAN, Darell BIGNER, Chien-Tsun KUAN, Gregory J. RIGGINS
-
Publication number: 20120115735Abstract: There are currently few therapeutic options for patients with pancreatic cancers and new insights into the pathogenesis of this lethal disease are urgently needed. To this end, we performed a comprehensive analysis of the genes altered in 24 pancreatic tumors. First, we determined the sequences of 23,781 transcripts, representing 20,583 protein-encoding genes, in DNA from these tumors. Second, we searched for homozygous deletions and amplifications using microarrays querying ˜one million single nucleotide polymorphisms in each sample. Third, we analyzed the transcriptomes of the same samples using SAGE and next-generation sequencing-by-synthesis technologies. We found that pancreatic cancers contain an average of 63 genetic alterations, of which 49 are point mutations, 8 are homozygous deletions, and 6 are amplifications. Further analyses revealed a core set of 12 regulatory processes or pathways that were each genetically altered in 70% to 100% of the samples.Type: ApplicationFiled: September 3, 2009Publication date: May 10, 2012Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Bert Vogelstein, Kenneth W. Kinzler, D. Williams Parsons, Sian Jones, Xiaosong Zhang, Jimmy Cheng-Ho Lin, Rebecca J. Leary, Philipp Angenendt, Nickolas Papadopoulos, Victor Velculescu, Giovanni Parmigiani, Rachel Karchin, Scott Kern, Ralph Hruban, James R. Eshleman, Michael Goggins, Alison Klein
-
Publication number: 20110229479Abstract: We found mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas as well as in glioblastomas that develop from these lower grade lesions. Those tumors without mutations in IDH1 often had mutations at the analogous R172 residue of the closely related IDH2 gene. These findings have important implications for the pathogenesis and diagnosis of malignant gliomas.Type: ApplicationFiled: September 3, 2009Publication date: September 22, 2011Applicants: THE JOHNS HOPKINS UNIVERSITY, DUKE UNIVERSITYInventors: Bert Vogelstein, Kenneth W. Kinzler, D. Williams Parsons, Xiaosong Zhang, Jimmy Cheng-Ho Lin, Rebecca J. Leary, Philipp Angenendt, Nickolas Papadopoulos, Victor Velculescu, Giovanni Parmigiani, Rachel Karchin, Sian Jones, Hai Yan, Darell Bigner, Chien-Tsun Kuan
-
Publication number: 20090123928Abstract: Human cancer is caused by the accumulation of mutations in oncogenes and tumor suppressor genes. To catalogue the genetic changes that occur during tumorigenesis, we isolated DNA from 11 breast and 11 colorectal tumors and determined the sequences of the genes in the Reference Sequence database in these samples. Based on analysis of exons representing 20,857 transcripts from 18,191 genes, we conclude that the genomic landscapes of breast and colorectal cancers are composed of a handful of commonly mutated gene “mountains” and a much larger number of gene “hills” that are mutated at low frequency. We describe statistical and bioinformatic tools that may help identify mutations with a role in tumorigenesis. These results have implications for understanding the nature and heterogeneity of human cancers and for using personal genomics for tumor diagnosis and therapy.Type: ApplicationFiled: October 8, 2008Publication date: May 14, 2009Applicant: The Johns Hopkins UniversityInventors: Laura D. Wood, Williams D. Parsons, Sian Jones, Jimmy Lin, Tobias Sjoblom, Thomas Barber, Giovanni Parmigiani, Victor Velculescu, Kenneth W. Kinzler, Bert Vogelstein
-
Patent number: 6849422Abstract: A system and method for analyzing samples, such as biological samples, to accurately and effectively determine the susceptibility of the samples to antimicrobial materials, so as to determine minimum inhibitory concentration (MIC) values for the respective samples and antimicrobial materials. At each of a plurality of time intervals, the system and method directs a plurality of different analyzing light wavelengths, such as red, green and blue wavelengths, onto each of a plurality of sample wells, and detects a respective resultant light wavelength emanating from the respective sample wells for each of the analyzing light wavelengths. The system and method uses resultant light wavelengths to generate at least two growth indicator characteristic curves representing, for example, the redox state and turbidity characteristics of the sample wells.Type: GrantFiled: May 31, 2000Date of Patent: February 1, 2005Assignee: Becton, Dickinson and CompanyInventors: Timothy M. Wiles, David J. Turner, Michael A. O'Connell, Giovanni Parmigiani, Merlise Clyde
-
Publication number: 20040063168Abstract: A system and method for analyzing samples, such as biological samples, to accurately and effectively determine the susceptibility of the samples to antimicrobial materials, so as to determine minimum inhibitory concentration (MIC) values for the respective samples and antimicrobial materials. At each of a plurality of time intervals, the system and method directs a plurality of different analyzing light wavelengths, such as red, green and blue wavelengths, onto each of a plurality of sample wells, and detects a respective resultant light wavelength emanating from the respective sample wells for each of the analyzing light wavelengths. The system and method uses resultant light wavelengths to generate at least two growth indicator characteristic curves representing, for example, the redox state and turbidity characteristics of the sample wells.Type: ApplicationFiled: October 27, 2003Publication date: April 1, 2004Inventors: Timothy M. Wiles, David J. Turner, Michael A. O'Connell, Giovanni Parmigiani, Merlise Clyde